Cellculture and transient protein expression are part of the expertise Magellan Biologics & Consulting offers to the scientific research community, therefore contributing to the progress of science biology and medicine for the benefit of patients.
We continuously develop our processes and products to propose the most advanced solutions in terms of yield of recombinant proteins, reproducibility and efficiency.
A novel drug produced in CHO cells has recently been approved by the FDA
Tislelizumab-jsgr is a PD-1 blocking antibody indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic
29 March 2024
